ShiraTronics Series B Raises $66M

Minneapolis, MN, October 9, 2024 (PR Newswire) -- ShiraTronics secures $66 million in Series B financing to propel the development of its innovative neurostimulation therapy for chronic migraine. The investment, led by Norwest Venture Partners and supported by a consortium of new and existing investors, aims to advance pivotal clinical trials and FDA approval efforts. Initial results from their Migraine Therapy System show promising early benefits, potentially reshaping treatment paradigms for millions suffering from treatment-resistant chronic migraine in the United States.

Read full article here.